Project description
PI3K signalling activation as an anti-cancer strategy
Phosphoinositide 3-kinase (PI3K) signalling is central for many biological functions and exhibits aberrant regulation in cancer. The EU-funded PI3K MODULATORS project aims to hyper-activate PI3K signalling in white blood cells as a therapeutic intervention for haematological malignancies. For this purpose, researchers will undertake a high-throughput screening approach to discover small-molecule PI3K activators specific for the white blood cell isoform of PI3K. They will study the mode of action of these activators as well as the mechanism of PI3K-mediated cancer cell death through various structural and biochemical analyses. The project's results will pave the way for the exploitation of PI3K drugs in cancer therapy.
Objective
PI3K signalling is a critical regulator of many cellular functions including cell growth and survival, and is deregulated in cancer and auto-immunity.
This proposal is based on the concept to cause cell death by hyperactivating signalling in cancer cells above a tolerable threshold. This idea has been previously proposed for other kinases, but no small-molecule activators were available to formally test the idea.
This proposal focuses on activators of the leukocyte-enriched PI3Kd, an isoform of PI3K that is involved in immune regulation and haematological malignancies.
The 3 key objectives and their approaches are:
1. To discover and characterise small-molecule PI3Kd activators. This will be achieved using a combination of virtual screening and high throughput screening.
2. To understand the mechanism of PI3Kd activation. This enables understanding of how these activators function, and provides structural data that can be used for structure-based design and compound improvement. This will be achieved using structural biology (HDX-MS and crystallography), biochemical (lipid kinase) and biophysical (binding) assays.
3. To determine the activity of PI3Kd activators in haematopoietic malignancies. In order to use PI3Kd activators in cancer therapy, it is critical to determine the conditions under which hyperactivation of PI3Kd results in cancer cell death. This will be achieved with a panel of B and T-cell lymphoma cell lines using cell viability assays under different conditions.
These objectives integrate my expertise in compound screening, molecular modelling and compound design with the world-leading expertise of the Host Lab in PI3K signalling, cancer biology and drug development. This proposal aims to make breakthroughs in understanding PI3K signalling, its exploitation in drug development and in cancer-therapy. This will be a key turning point in my scientific career and facilitate PI3K drug development collaborations of the Host Lab with the pharmaceutica.
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural sciencesearth and related environmental sciencesgeologymineralogycrystallography
- natural sciencesbiological sciencesbiochemistrybiomoleculeslipids
- medical and health sciencesclinical medicineoncology
- natural sciencesbiological sciencesmolecular biologystructural biology
Programme(s)
Funding Scheme
MSCA-IF-EF-ST - Standard EFCoordinator
WC1E 6BT London
United Kingdom